NICE has recommended mirvetuximab soravtansine, also known as Elahere, for adults in England with folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. The decision marks the first new NHS treatment for this form of ovarian cancer in more than 20 years, according to the agency.
A targeted option after chemotherapy stops working
The treatment is designed for patients whose cancer has stopped responding to standard chemotherapy within six months. NICE said the drug uses a targeted approach that seeks out a specific protein on the surface of cancer cells and delivers medicine directly to them. It will be given as an intravenous infusion by a doctor or nurse with experience in cancer medicines, with the dose calculated by body weight.
According to NICE, the recommendation follows an evidence-based evaluation and a new commercial arrangement between AbbVie and NHS England. The treatment will be available immediately through the Cancer Drugs Fund before later moving to the routine commissioning budget 90 days after final guidance is published.
Clinical data showed longer survival and slower progression
NICE said trial data from the MIRASOL study, which involved 453 adults, showed women receiving mirvetuximab soravtansine lived an average of 16.9 months compared with 13 months for those receiving chemotherapy. The agency also said disease progression was delayed, with an average of 5.6 months before the cancer worsened, compared with 4 months in the chemotherapy group.
The agency added that around 270 people are expected to be eligible in the first year, rising to approximately 420 by year three as access to the diagnostic test needed to confirm eligibility becomes more widely available.
Patients described a different treatment experience
NICE said women involved in its evaluation highlighted the burden of chemotherapy, describing frequent hospital visits, extreme fatigue, hair loss, nausea and long-term nerve damage. The agency said patients described chemotherapy as putting their lives on hold, leading to isolation, inability to work and dependence on others for support.
Helen Knight, director of medicines evaluation at NICE, said the recommendation was the result of a thorough, evidence-based evaluation by an independent committee. Lucy Common, clinical nursing advisor at NICE, said the new treatment offers not just longer survival but a meaningfully different treatment experience with fewer hospital visits and a more manageable side effect profile.
Why the decision matters for women with platinum-resistant disease
The recommendation follows a period in which treatment options for this stage of ovarian cancer were limited. NICE said the new therapy offers a targeted alternative for women living with a difficult-to-treat cancer, while patient groups welcomed the announcement as an important breakthrough and a chance to improve quality of life.
Mirvetuximab soravtansine is recommended for adults whose tumours carry folate receptor-alpha and who have already had between one and three previous treatments. NICE said the medicine represents good use of NHS resources, taking into account the severity of the condition.
For a disease that has long had few effective options once chemotherapy no longer works, the recommendation could offer a new route to treatment and, for some patients, more time with a less disruptive care experience.
Source: NICE news article
